Medicamen Biotech Ltd (MEDICAMEQ) — FY26 Annual Report | 3 September 2026 (2 announcements)

Medicamen Biotech Ltd held its 33rd AGM on September 26, 2026 via video conferencing, approving its FY2025-26 Annual Report. The company reported 18.1% revenue growth to ₹178.84 Crores, ₹9.41 Crores PAT, and declared a ₹1 per share dividend (10%). Key growth drivers included oncology expansion, international markets (Europe, Africa), and 71% sales growth in Medicamen Lifesciences. Governance updates featured new independent directors, committee reconstitutions, and compliance with SEBI regulations. Two material related party transactions with Shivalik Rasayan Limited (up to ₹30 Crores) and subsidiary Medicamen Life Sciences (up to ₹30 Crores) were approved, both representing ~15% of turnover. The Board emphasized sustainable growth through integrated manufacturing, R&D, and regulatory capabilities.

Medicamen Biotech Ltd announced its 33rd AGM on September 26, 2026 via video conference, alongside filing its FY 2025-26 Integrated Annual Report. The report highlights 18.1% revenue growth to ₹178.84 Crores, 49.43% PAT growth to ₹979.64 Lakhs, and a final dividend of ₹1 per share (10% on ₹10 face value). Key growth drivers include oncology expansion, international markets (Europe, Africa), and strong domestic branded sales across 9 states with 112 KOLs and 10,000+ doctors. The company raised [amount not verified] through a preferential issue of 8,48,215 equity shares and 6,50,000 convertible warrants at ₹530 per share. Governance updates include new independent directors (Sham Goel, Shaival Saurabh) and board reappointments. Two material related party transactions were approved with Shivalik Rasayan Limited for API procurement and services up to ₹30 Crores annually. The filing also details regulatory compliance, including penalties for delayed shareholding filings and committee composition issues.